
GDF-8 (Myostatin)
Research Peptide | Lyophilized Powder | Batch Tested
For laboratory research use only. Not for human or animal consumption. Insulated shipping · Styrofoam box available.
Product Overview
GDF-8 (myostatin) is a member of the TGF-β superfamily that acts as the body's primary negative regulator of skeletal-muscle mass. It is studied both as a target for inhibition and as a reference ligand for understanding muscle-growth restraint.
| Test | Result | Status |
|---|---|---|
| Purity | 99.5% | Passed ✓ |
Research Information
GDF-8 is used as a reference ligand to study the ActRIIB/Smad2-3 signaling pathway that limits muscle growth, and to characterize antagonists, decoy receptors and binding proteins in muscle-development research. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption.
GDF-8 (Myostatin) Research & Studies
What is GDF-8 (Myostatin)?
GDF-8, commonly called myostatin, is a secreted glycoprotein of the transforming growth factor-beta (TGF-β) superfamily. In laboratory settings it is recognized as a principal negative regulator of skeletal-muscle mass. Researchers employ recombinant GDF-8 as a reference ligand to probe the molecular restraints that limit myofiber growth and to evaluate tools that modulate this pathway. The material is supplied strictly for in-vitro and laboratory research use.
Mechanism of Action
GDF-8 binds with high affinity to activin type II receptors, predominantly ActRIIB, on the cell surface. Receptor engagement triggers phosphorylation of Smad2 and Smad3, which then form complexes that translocate to the nucleus and repress genes supporting myoblast proliferation and protein synthesis. This ActRIIB/Smad2-3 cascade is the central signaling route examined in muscle-development studies. Experimental systems use purified GDF-8 to quantify pathway activation and to characterize intervening antagonists.
Primary Areas of Research
Investigators utilize GDF-8 to map the ActRIIB/Smad2-3 axis that restrains muscle hypertrophy in cell-culture and biochemical assays. The ligand serves as a standard for screening decoy receptors, monoclonal antibodies, and endogenous binding proteins such as follistatin. Additional work explores cross-talk between GDF-8 and other TGF-β family members in myogenic differentiation models. All applications remain confined to controlled laboratory environments.
Key Research Findings
Genetic ablation or functional blockade of GDF-8 in model systems consistently produces elevated skeletal-muscle mass, confirming its role as a growth-limiting factor. In vitro studies demonstrate that recombinant GDF-8 suppresses myoblast proliferation and differentiation through Smad-dependent transcriptional repression. Binding proteins and soluble ActRIIB constructs have been shown to neutralize GDF-8 activity in ligand-binding and reporter assays. These observations underpin ongoing characterization of pathway modulators.
Research Handling & Considerations
Recombinant GDF-8 preparations require cold-chain storage and careful reconstitution to preserve receptor-binding activity for in-vitro work. Dilution and assay buffers should follow established laboratory protocols for TGF-β family ligands. The compound is intended solely for cell-based signaling studies, receptor-binding experiments, and antagonist characterization. Standard biosafety practices for recombinant proteins apply at all times.
Frequently Asked Questions
GDF-8 is studied as a reference ligand to examine the ActRIIB/Smad2-3 pathway that limits skeletal-muscle growth and to evaluate antagonists, decoy receptors, and binding proteins in controlled in-vitro systems.
Explore Other High-Purity Peptides

Ipamorelin

CJC-1295 (No DAC)

Sermorelin
